[{"address1": "64 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 588 5555", "fax": "617 588 5554", "website": "https://vcel.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 314, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dominick C. Colangelo Esq.", "age": 59, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1543339, "exercisedValue": 1513939, "unexercisedValue": 35048676}, {"maxAge": 1, "name": "Mr. Joseph Anthony Mara Jr.", "age": 47, "title": "CFO & Treasurer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 750614, "exercisedValue": 0, "unexercisedValue": 70168}, {"maxAge": 1, "name": "Mr. Michael  Halpin", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 796913, "exercisedValue": 492260, "unexercisedValue": 3420103}, {"maxAge": 1, "name": "Mr. Sean C. Flynn", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 657013, "exercisedValue": 0, "unexercisedValue": 2566220}, {"maxAge": 1, "name": "Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 672165, "exercisedValue": 127250, "unexercisedValue": 1785364}, {"maxAge": 1, "name": "Mr. Jonathan D. Siegal", "title": "Principal Accounting Officer, VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Burns", "title": "Vice President of Finance & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick J. Fowler", "title": "Senior Vice President of Corporate Development & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  Helfrich", "title": "Vice President of Marketing & Commercial Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Gilligan", "title": "Senior Vice President of Sales", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 2, "compensationRisk": 6, "shareHolderRightsRisk": 4, "overallRisk": 4, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 43.74, "open": 44.16, "dayLow": 43.88, "dayHigh": 45.72, "regularMarketPreviousClose": 43.74, "regularMarketOpen": 44.16, "regularMarketDayLow": 43.88, "regularMarketDayHigh": 45.72, "beta": 1.729, "forwardPE": 92.61224, "volume": 291722, "regularMarketVolume": 291722, "averageVolume": 449487, "averageVolume10days": 336440, "averageDailyVolume10Day": 336440, "bid": 45.38, "ask": 45.51, "bidSize": 100, "askSize": 100, "marketCap": 2195507200, "fiftyTwoWeekLow": 29.24, "fiftyTwoWeekHigh": 53.05, "priceToSalesTrailing12Months": 11.115592, "fiftyDayAverage": 47.4006, "twoHundredDayAverage": 38.60155, "currency": "USD", "enterpriseValue": 2169893632, "profitMargins": -0.01611, "floatShares": 44658744, "sharesOutstanding": 48380500, "sharesShort": 4394197, "sharesShortPriorMonth": 2274344, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0908, "heldPercentInsiders": 0.00838, "heldPercentInstitutions": 1.12386, "shortRatio": 8.38, "shortPercentOfFloat": 0.1457, "bookValue": 4.724, "priceToBook": 9.606266, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": 1.194, "netIncomeToCommon": -3182000, "trailingEps": -0.07, "forwardEps": 0.49, "lastSplitFactor": "1:20", "lastSplitDate": 1381881600, "enterpriseToRevenue": 10.986, "enterpriseToEbitda": -1184.44, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "VCEL", "underlyingSymbol": "VCEL", "shortName": "Vericel Corporation", "longName": "Vericel Corporation", "firstTradeDateEpochUtc": 855066600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f46775e8-0ff4-3560-a86f-60297a1259db", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.38, "targetHighPrice": 57.0, "targetLowPrice": 47.4, "targetMeanPrice": 53.9, "targetMedianPrice": 55.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 109557000, "totalCashPerShare": 2.269, "ebitda": -1832000, "totalDebt": 88043000, "quickRatio": 3.67, "currentRatio": 4.495, "totalRevenue": 197516000, "debtToEquity": 38.965, "revenuePerShare": 4.15, "returnOnAssets": -0.01289, "returnOnEquity": -0.0152199995, "freeCashflow": -10960000, "operatingCashflow": 35311000, "earningsGrowth": 1.045, "revenueGrowth": 0.233, "grossMargins": 0.68641, "ebitdaMargins": -0.00928, "operatingMargins": 0.19587, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]